Literature DB >> 7535702

CD8+ and CD45RA+ human peripheral blood lymphocytes are potent sources of macrophage inflammatory protein 1 alpha, interleukin-8 and RANTES.

K Conlon1, A Lloyd, U Chattopadhyay, N Lukacs, S Kunkel, T Schall, D Taub, C Morimoto, J Osborne, J Oppenheim.   

Abstract

The chemokines macrophage inflammatory protein 1 alpha (MIP 1 alpha), interleukin-8 (IL-8) and RANTES are potent regulators of leukocyte trafficking. Examination of chemokine secretion by human peripheral blood lymphocytes after stimulation with anti-CD3 or phorbol 12, 13 myristate acetate and ionomycin showed CD8+ cells were the dominant source of MIP 1 alpha and RANTES. Although production of MIP 1 alpha and IL-8 were similar in pharmacologically stimulated CD4+ CD45RA+, CD4+ CD45RO+, and CD8+ CD45RA+ cells, the largest amounts of MIP 1 alpha and RANTES were secreted by CD8+ CD45RO+ lymphocytes. A parallel pattern of prolonged chemokine mRNA expression for at least 18 h after activation was observed in the T cells subsets. These results confirm that human T lymphocytes have a unique capacity for secretion of these three chemokines. In addition, CD8+ cells have an unrecognized role in recruiting cells to sites of inflammation, and adult human CD45RA+ cells have a physiologically significant secretory capacity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535702     DOI: 10.1002/eji.1830250319

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

Review 1.  Current concepts in human immunodeficiency virus infection and AIDS.

Authors:  S A Schwartz; M P Nair
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection.

Authors:  F Cocchi; A L DeVico; R Yarchoan; R Redfield; F Cleghorn; W A Blattner; A Garzino-Demo; S Colombini-Hatch; D Margolis; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Do beta-chemokines have clinical relevance in HIV infection?

Authors:  C E Mackewicz; E Barker; G Greco; G Reyes-Teran; J A Levy
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

4.  Elevated levels of beta-chemokines in bronchoalveolar lavage fluid (BALF) of individuals infected with human T lymphotropic virus type-1 (HTLV-1).

Authors:  M Seki; J I Kadota; Y Higashiyama; K Iida; T Iwashita; E Sasaki; S Maesaki; K Tomono; S Kohno
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

5.  CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines.

Authors:  R S Kornbluth; K Kee; D D Richman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

6.  Granular cell tumor of the esophagus: a clinicopathological study of 31 cases.

Authors:  Ling Nie; Guifang Xu; Hongyan Wu; Qin Huang; Qi Sun; Xiangshan Fan
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

7.  Analysis of T cell subsets and beta chemokines in patients with pulmonary sarcoidosis.

Authors:  K Iida; J Kadota; K Kawakami; Y Matsubara; R Shirai; S Kohno
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

8.  Transcriptional profiling of experimental CD8(+) lymphocyte depletion in rhesus macaques infected with simian immunodeficiency virus SIVmac239.

Authors:  Steven E Bosinger; Simon P Jochems; Kathryn A Folkner; Timothy L Hayes; Nichole R Klatt; Guido Silvestri
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

9.  Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis.

Authors:  J J Haringman; M C Kraan; T J M Smeets; K H Zwinderman; P P Tak
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

10.  Functional characterization of human Tc0, Tc1 and Tc2 CD8+ T cell clones: control of X4 and R5 HIV strain replication.

Authors:  Michèle Février; Sylvie le Borgne; Christian Marty; Antoine Talarmin; Yves Rivière
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.